GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Molecular Dx Has Your (Copy) Number
CNV Detection and Analysis Tools Are Being Used To Fill Genetic Diagnostic Gaps
For full access to this article login to GEN Select now.
Complex Biosimilars Demand New Rules
Case-by-Case Decision-Making Process May Be Best Approach for Safe and Efficacious Drugs
- More than $10 billion worth of biologics are expected to be off-patent by 2010, creating enormous incentives for the development of generic alternatives to these drugs. As a result, it is anticipated that the market for biosimilars will grow significantly in the coming years. For companies with extensive ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.